This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Chelsea Therapeutics: Northera FDA Panel Live Blog

A panel of experts is debating the merits of Chelsea's drug as a treatment for a debilitating form of low blood pressure. Follow along with our live blog.

Unigene Faces Do-or-Die FDA Panel Tuesday

An FDA panel's decision on the safety of calcitonin to treat osteoporosis will have a big impact on Unigene's stock price.

Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results

TheStreet contributor Aafia Chaudhry says prior study results raise the risk of a bad outcome in Ziopharm's phase III sarcoma drug trial.

Sarepta Bear Speaks: Eteplirsen Accelerated Approval Will Be Denied

Eteplirsen data are biased and flimsy, and FDA will ask for another clinical trial, says TheStreet contributor Aafia Chaudhry.

Depomed Bear Case: FDA Panel Will Ding Serada

New contributor Aafia Chaudhry explains why she believes Depomed's hot flash drug has no future.

Page 1 of 1
< Previous
Next >
Top Rated Stocks Top Rated Funds Top Rated ETFs